Endometrial injury
Conditions
Interventions
Experimental Group:Receive 0.5ml of 3D exosomes combined with 0.5ml of sodium hyaluronate once a week for a total of three treatments
Control group:Receive 0.5ml of normal saline (0.9% sodium chloride solution) combined with 0.5ml of sodium hyaluronate once a week for a total of three treatments
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1.Age: 20 to 45 years old, female, body mass index 1.1ng/ml; 6.The TCT test results are normal within one year or both TCT and HPV test results are normal within three years; 7.With full informed consent, voluntarily participate in this study and be able to complete the follow-up on schedule.
Exclusion criteria
Exclusion criteria: 1. Anyone suffering from serious cardiovascular, lung, liver and kidney diseases; Suffering from chronic diseases: diabetes, hypertension, blood disorders, embolic diseases, autoimmune diseases, etc. There are concurrent diseases that seriously endanger patient safety or affect the patient's completion of this study; 2. Those who have not been cured of STI such as AIDS, syphilis, Neisseria gonorrhoeae or chlamydia, as well as those who have not been cured of vaginitis, pelvic inflammatory disease or reproductive tract infectious diseases; Those who have not been cured of alcoholism, drug abuse or drug addiction; 3. Presence of malignant tumors or suspected malignant tumors; 4. There are organic uterine lesions such as uterine malformations, adenomyosis, uterine fibroids, and endometrial hyperplasia, as well as reproductive organ lesions such as hydrosalpinx or ovarian cysts; 5. Those who were pregnant before inclusion or had sexual activity after the onset of menstruation; 6. Suffering from mental illness, including severe hysteria, and lacking autonomy; 7. History of severe allergies or severe immune deficiency; 8. Poor compliance; 9. Participated in other experimental studies in the past three months; 10. Unable to understand the researcher's introduction or explanation of this study; 11. Other circumstances where the researcher deems it unsuitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effective rate of improvement in endometrial thickness during the luteal phase; | — |
Secondary
| Measure | Time frame |
|---|---|
| Effective rate of improvement in endometrial thickness during the luteal phase (process);Menstrual blood volume;Endometrial morphology;Self-satisfaction evaluation of the treatment effect by the subjects; | — |
Countries
China
Contacts
Public ContactMo Xiaoliang
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed